SCHEMBL7960735

SCHEMBL7960735

CN(C=O)/C(N)=N\C1CC(c2ccccc2)Oc2ccccc21

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.34
ADORA3 P0DMS8 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
AR P10275 2/20 0.34
MAOB P27338 2/20 0.34
CFTR P13569 1/20 0.33
LTA4H P09960 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
HSD11B1 P28845 1/20 0.31
AKR1C3 P42330 1/20 0.31
NPC1 O15118 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
RAB9A P51151 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7960933 0.84 CFTR (0.34) CYP19A1ADORA3KDM4EHSD17B10AR
SCHEMBL12299575 0.81 GPR88 (0.36) MAOBALDH1A1CYP3A4
SCHEMBL7958664 0.74 AR (0.31) CYP19A1ARCFTR
SCHEMBL7958731 0.73 FADS1 (0.37) MAOB
SCHEMBL10367427 0.69 SIGMAR1 (0.38) CYP19A1ADORA3KDM4EHSD17B10AR
SCHEMBL27412212 0.68 MAOB (0.45) CYP19A1ADORA3KDM4EHSD17B10AR
SCHEMBL10366584 0.67 MAOB (0.41) CYP19A1ADORA3KDM4EHSD17B10AR
SCHEMBL1267388 0.66 CYP19A1 (0.45) CYP19A1ADORA3KDM4EHSD17B10AR
SCHEMBL13176790 0.66 MAOB (0.45) CYP19A1ADORA3KDM4EHSD17B10AR
SCHEMBL380283 0.66 CYP19A1 (0.45) CYP19A1ADORA3KDM4EHSD17B10AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP CYP19A1 1456/4885ADORA3 4489/4885KDM4E 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.